CD274 and esophageal cancer: A number of clinical trials of PD-1/PD-L1 signal-blockade agents as immune checkpoint inhibitors (ICIs) have recently demonstrated dramatic antitumor efficacy in patients with numerous types of malignancy, including esophageal cancer [6, 7].